AbbreviationsDSSdisease‐specific survivalEBRTexternal beam radiotherapyESTSextremity soft tissue sarcomaHILPhyperthermic isolated limb perfusionIRBinstitutional review boardIQRinterquartile rangeLRFSlocal recurrence free survivalLSTlimb salvage treatmentMPNSTmalignant peripheral nerve sheath tumorOSoverall survivalSTSsoft tissue sarcomasUMCGUniversity Medical Center GroningenINTRODUCTIONSoft tissue sarcomas (STS) are rare, malignant tumors with an incidence of 12 310 new cases in the United States and 729 in the Netherlands in 2016, resulting in 4990/300 STS related deaths in the United States and in the Netherlands in 2016. STS form a heterogeneous group of tumors including more than 50 different histologic subtypes. The most common subtypes are pleomorphic undifferentiated sarcoma (including malignant fibrous histiocytoma), liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor, which account for a total of 76% of all STS. STS can occur at any anatomic location but most often arise in the limbs (60‐70%). Despite complete resection, with or without (neo)adjuvant treatment, STS are known for their potential to recur locally and/or to cause distant metastases, mainly to the lungs. The available data considering the improvement of survival following (neo)adjuvant systemic chemotherapy are inconsistent and under on‐going investigation.Amputation does not increase the survival rate of patients with extremity soft tissue sarcoma (ESTS) when compared with limb salvage surgery combined with (postoperative) radiotherapy. So,
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera